Search clinical trials for: 200 U EV71 vaccine with adjuvant

Total 112 results

Sinovac Biotech Co., Ltd

Completed

Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants

Infection, Viral, Enterovirus

China
Sinovac Biotech Co., Ltd

Withdrawn

Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants

Infection, Viral, Enterovirus

China
Sinovac Biotech Co., Ltd
Guangdong Center for Disease Prevention and Control

Completed

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

Hand, Foot and Mouth Disease

China
Jiangsu Province Centers for Disease Control and...
Bejing Vigoo Biological Co., LTD

Completed

A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

Safety | Immunogenicity

China
Enimmune Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old

Enterovirus Infections

Taiwan
Enimmune Corporation

Completed

A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects

Enterovirus Infections

Taiwan
Sinovac Biotech Co., Ltd
Shaanxi Provincial Center for Disease Control and Prevention

Completed

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

Hand, Foot and Mouth Disease

China
Colby Pharmaceutical Company

Completed

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant (H-100-001)

Influenza

United States
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Hepatitis B

Germany, United Kingdom, Belgium
Sinovac Biotech Co., Ltd

Completed

Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children

Hand-foot-mouth Disease | Infection; Viral, Enterovirus

China
Novavax

Completed

Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine

Covid19 | SARS-CoV Infection

Australia
Novavax
PATH

Completed

RSV-F Vaccine Dose Ranging Study in Young Women

Respiratory Syncytial Virus (RSV)

United States
DynPort Vaccine Company LLC, A GDIT Company

Completed

Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

Plague Vaccine

United States
GlaxoSmithKline

Completed

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

Influenza | Influenza Vaccines

Taiwan, Hong Kong, Thailand, Singapore
Novartis
Novartis Vaccines

Completed

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Influenza Infection

Switzerland
Medigen Vaccine Biologics Corp.

Completed

A Clinical Study for Inactivated Vaccine Against EV71 (EV71)

Enterovirus 71 Human

Taiwan
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

H7N9 Influenza Vaccine

Taiwan
Colby Pharmaceutical Company

Completed

Safety, Tolerability and Immunogenicity of Fluzone® With and Without JVRS-100 in Elderly Subjects

Influenza
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002)

Dengue Fever

Puerto Rico
GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects

Influenza

Italy
Bill & Melinda Gates Medical Research Institute
Iqvia Pty Ltd

Withdrawn

Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion

Influenza
GlaxoSmithKline

Completed

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

Tuberculosis

Belgium
Madhu Chhanda Choudhary
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy (NETI)

HIV Infections

United States
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
GlaxoSmithKline

Completed

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.

Tuberculosis

Switzerland
Yisheng Biopharma (Singapore) Pte. Ltd.
Duke-NUS Graduate Medical School

Completed

Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant

Rabies

Singapore
Novartis Vaccines

Completed

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects

Influenza

Italy
International Vaccine Institute
Massachusetts General Hospital; EuBiologics Co.,Ltd

Recruiting

Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults

Cholera Vaccination Reaction

Korea, Republic of
Yisheng Biopharma (Singapore) Pte. Ltd.

Completed

Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen

Rabies

Singapore
Novavax

Completed

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

Respiratory Syncytial Viruses

Australia
Nova Immunotherapeutics Limited
The Emmes Company, LLC; Nova Laboratories Limited; Mercia Pharma Inc.

Unknown

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) (MER4101)

Influenza, Human

United States
Biomedical Advanced Research and Development Authority

Completed

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Influenza A Virus, H5N1 Subtype

United States
Pfizer

Completed

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Clostridium Difficile

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

HIV Infections

United States
Bristol-Myers Squibb
National Cancer Institute (NCI)

Withdrawn

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Melanoma (Skin)
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection

Diarrhea | Clostridium Difficile Infection

United Kingdom, United States
Novavax

Completed

A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age

Respiratory Synctial Virus

Canada
PX'Therapeutics
European Commission

Completed

Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine

- HIV

United Kingdom
NovaDigm Therapeutics, Inc.
United States Department of Defense

Completed

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Candidiasis | Staphylococcal Infections | Yeast Infections

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
University of Wisconsin, Madison

Completed

HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders

Healthcare Worker, Hepatitis B Vaccine, Nonresponder

United States
Novavax
Bill and Melinda Gates Foundation

Completed

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

Respiratory Syncytial Virus Infections

United States, Argentina, Australia, Bangladesh, Chile, Mexico, New Zealand, Philippines, South Africa, Spain, United Kingdom
Sanofi

Completed

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Novavax

Completed

A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) (COVID-19)

SARS-CoV-2 Infection

South Africa
The University of Hong Kong

Completed

Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients

Hepatitis B | Inflammatory Bowel Diseases

China
Institut Pasteur
Wellcome Trust; Walter Reed Army Institute of Research (WRAIR); Parexel; Bill &... and other collaborators

Completed

A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a (GlycoShig3)

Healthy

Kenya
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Children

Influenza

United States
Novavax

Completed

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Respiratory Syncytial Virus (RSV)

United States
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP); Institut...

Completed

Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Malaria,Falciparum

Burkina Faso

3

Subscribe